Embecta Corp. is a healthcare company that focuses on the development and manufacturing of products for people living with diabetes. The company specializes in diabetes management solutions, including insulin delivery systems and other related devices, aimed at improving the quality of life for patients. With a commitment to innovation, Embecta aims to enhance the safety and efficiency of diabetes care, ultimately contributing to better health outcomes for individuals managing this chronic condition. Its comprehensive portfolio is designed to address the diverse needs of users, from novice patients to experienced individuals, ensuring accessible and effective technologies in diabetes therapy. Read More
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Embecta (EMBC) To Contact Him Directly To Discuss Their Options
Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Embecta Corp. (NASDAQ: EMBC) between November 25, 2025 and May 4, 2026. Embecta describes itself as a “leading global medical device company focused on providing solutions to improve the health and well-being of people living with diabetes.”
The Law Offices of Frank R. Cruz announces an investigation of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ: EMBC) on behalf of investors concerning the Company’s possible violations of federal securities laws.
The DJS Law Group reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Embecta Corp. (NASDAQ: EMBC) securities between November 25, 2025 and May 4, 2026. Embecta Corp., is a medical device company, that provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally.
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Embecta Corp. (“Embecta” or “the Company”) (NASDAQ: EMBC) for violations of the securities laws.
NEW YORK, May 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Embecta (EMBC) To Contact Him Directly To Discuss Their Options
NEW YORK, May 27, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP continues its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.
The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Embecta Corp. (“Embecta” or the “Company”) (NASDAQ:EMBC) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws or other unlawful business practices.
Embecta (NASDAQ:EMBC) President and CEO Devdatt Kurdikar said the company’s recent U.S. business reset reflected a combination of customer-specific share loss, softer market trends and inventory-related factors, while emphasizing that the diabetes device maker is continuing a broader diversification
As of April 3, 2026, the medical technology landscape is undergoing a radical transformation, and few companies embody this evolution more than Becton, Dickinson and Company (NYSE: BDX). Known colloquially as BD, the firm has spent the last two years shedding its skin, moving from a broad-based healthcare conglomerate to a high-growth, high-margin "pure-play" medical [...]
Today, February 9, 2026, marks a watershed moment for Becton, Dickinson and Company (NYSE: BDX). The medical technology giant, commonly known as BD, has officially closed its transformative $17.5 billion combination with Waters Corporation (NYSE: WAT), effectively spinning off its Biosciences and Diagnostic Solutions units to create a more streamlined "New BD." Simultaneously, the company [...]
Today’s Date: January 9, 2026 Introduction In the rapidly evolving landscape of medical technology, few companies have managed to fundamentally reshape a multi-decade standard of care as successfully as Insulet Corporation (NASDAQ: PODD). Historically, insulin delivery was synonymous with either multiple daily injections (MDI) or cumbersome, tubed mechanical pumps. Insulet disrupted this paradigm with the [...]
